|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| NIAGARA Trial Shows Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer |
| Thomas Powles, MBBS, MRCP, MD |
| Thomas Powles joins Zachary Klaassen to discuss the NIAGARA trial results. The phase III study examines the addition of durvalumab to cisplatin-based chemotherapy in the perioperative setting for muscle-invasive bladder cancer, representing the largest trial in this space with 1,000 patients. |
|
|
|
|
|
|
|
|
|
|
|
| Belzutifan vs Everolimus Trial Data in Advanced RCC Care |
| Brian I. Rini, MD, FASCO |
| Brian Rini joins Pedro Barata to discuss the updated results of the Phase 3 LITESPARK-005 trial. The study, which led to belzutifan's approval in December 2023, compares belzutifan to everolimus in refractory clear cell RCC patients who previously received PD-1/PD-L1 and VEGF-TKI therapy. |
|
|
|
|
|
|
|
|
|
|
|
| TiNivo-2 Trial Results in Advanced Renal Cell Carcinoma Treatment |
| Toni Choueiri, MD |
| Toni Choueiri discusses the TiNivo-2 trial results, comparing tivozanib-nivolumab combination to tivozanib monotherapy in advanced clear cell renal cell carcinoma. The study, involving 343 patients, shows no benefit in rechallenging with nivolumab after prior immunotherapy. |
|
|
|
|
|
|
|
|
|
|
|
| Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials |
| Maria De Santis, MD, PhD |
| Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and the VOLGA trial exploring ctDNA clearance as a biomarker. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| AI in Prostate Cancer: Diagnostic Hype and Hope |
| Anobel Y. Odisho, MD, MPH, FAMIA |
| Anobel Odisho discusses the evolving role of AI in prostate cancer diagnosis, particularly focusing on prostate MRI. AI can enhance both image quality (through better acquisition, evaluation, and post-processing) and image interpretation, assisting in lesion detection, segmentation, and risk stratification. Studies have shown that AI models like ResNet50 outperform general radiologists in lesion classification, though fellowship-trained radiologists still achieve better results. |
|
|
|
|
|
| Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk NMIBC with UGN-102: A Single Arm, Open Label, Phase 3 Trial (ENVISION)
|
| Sandip M. Prasad, MD
|
| Sandip Prasad presented data from the ENVISION trial, a Phase 3 study evaluating UGN-102 as a primary chemoablative therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC). UGN-102 is a reverse thermal hydrogel containing mitomycin, administered via intravesical instillation. The trial enrolled 240 patients, with 79.6% achieving a complete response at 3 months.
|
|
|
|
|
|
|
|
|
|
|
| Update on Neoadjuvant Therapy Trials in RCC |
| Naomi Haas, MD |
| Naomi Haas provides an update on ongoing and completed neoadjuvant therapy trials in renal cell carcinoma (RCC), focusing on immune checkpoint inhibitors (ICIs), targeted therapies (TKIs), and their combinations. While safety has been established, trials have shown limited pathologic response or RECIST partial response, with a need for more effective approaches. |
|
|
|
|
|
|
|
| SBRT for Unfavorable Intermediate-Risk Prostate Cancer
|
| Daniel Spratt, MD
|
| Daniel Spratt discusses the role of SBRT in treating unfavorable intermediate-risk prostate cancer (UIR), emphasizing its potential benefits in terms of treatment duration and toxicity. He highlighted that while UIR prostate cancer is associated with poor prognosis and higher risks of distant metastasis, SBRT, delivered in as few as 5 fractions, offers a significant advancement over traditional radiation techniques. Dr. Spratt also noted ongoing trials, including the FORT and HERMES trials, which are investigating optimal SBRT schedules and their effectiveness compared to other radiation modalities for prostate cancer treatment.
|
|
|
|
|
|
|
|
| Dosimetry and Pilot Therapy Study of Novel PSMA-Targeting Agents, 177Lu-P17-087 and 177Lu-P17-088, in Metastatic Castration-Resistant Prostate Cancer Patients |
| Linlin Li |
| Linlin Li presents a study evaluating two novel PSMA-targeting agents, 177Lu-P17-087 and 177Lu-P17-088, for treating metastatic castration-resistant prostate cancer. The study assessed biodistribution, dosimetry, and preliminary efficacy, with both agents showing promising results in terms of tumor uptake and PSA response. While 177Lu-P17-088, with its albumin binding modification, demonstrated longer blood circulation and higher effective doses, both agents led to significant PSA reductions in several patients, suggesting their potential as effective alternatives to 177Lu-PSMA-617 for radioligand therapy. |
|
|
|
|
|
|
|
| PSMAfore: HRQoL and Pain in a Phase 3 Study of 177Lu-PSMA-617 in Taxane-Naïve Patients with mCRPC |
| Karim Fizazi, MD, PhD |
| Karim Fizazi presents results from the PSMAfore study, focusing on health-related quality of life (HRQoL) and pain outcomes in taxane-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with 177Lu-PSMA-617. This Phase 3 trial compared 177Lu-PSMA-617 to a change in androgen receptor pathway inhibitors (ARPI). The study showed that 177Lu-PSMA-617 significantly delayed worsening HRQoL (FACT-P and EQ-5D-5L) and pain (BPI-SF) scores compared to ARPI. |
|
|
|
|
|
|
|
|
|
|
| Characterization of Complete Responders to Nivolumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone and Patients with Lymph Node–Only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial
|
| Matt D. Galsky, MD, FASCO
|
| Matt Galsky presents a post hoc analysis of the CheckMate 901 trial, exploring complete responders (CR) to nivolumab plus gemcitabine-cisplatin (Nivolumab+GC) versus gemcitabine-cisplatin (GC) alone, with a particular focus on patients with lymph node-only metastatic urothelial carcinoma (mUC). The trial showed that Nivolumab+GC significantly improved overall survival (OS), progression-free survival (PFS), and response rates compared to GC alone.
|
|
|
|
|
|
| EAU 2024 |
| Extended Follow-Up from CheckMate 274 Including the First Report of Overall Survival Outcomes
|
| Matthew Galsky, MD
|
| Matthew Galsky presents extended follow-up data from the CheckMate 274 trial, including the first report of overall survival outcomes. Adjuvant nivolumab continued to show significant benefits in disease-free survival, non-urinary tract recurrence-free survival, and distant metastasis-free survival, with improved overall survival in both the intention-to-treat (HR 0.76) and PD-L1 ≥1% populations (HR 0.56). These findings support the use of nivolumab as a standard adjuvant treatment for high-risk muscle invasive urothelial carcinoma following radical surgery.
|
|
|
|
|
|
| ASCO GU 2024 |
| Overall Survival Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell RCC |
| Toni K. Choueiri, MD |
| Toni Choueiri presents overall survival results from the phase 3 KEYNOTE-564 study, which evaluated adjuvant pembrolizumab vs. placebo in patients with clear cell RCC at high risk of recurrence after nephrectomy. The study showed a statistically significant improvement in overall survival with pembrolizumab (HR 0.62, p = 0.0024), with a 38% reduction in the risk of death compared to placebo. These results, along with continued disease-free survival benefits, support pembrolizumab as a new standard of care for adjuvant treatment in this patient population. |
|
|
|
|
|
| Subcutaneous Nivolumab Versus Intravenous Nivolumab in Patients With Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Pharmacokinetics, Efficacy, and Safety Results From CheckMate 67T |
| Saby George, MD, FACP |
| Saby George presents results from CheckMate 67T, comparing subcutaneous nivolumab (NIVO SC) to intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell RCC. The study met its co-primary endpoints, demonstrating non-inferiority in pharmacokinetics and efficacy, with NIVO SC showing a higher objective response rate (60%) compared to NIVO IV (45%). The safety profiles of both treatment arms were similar, with NIVO SC offering faster administration (≤5 minutes), making it a viable option to reduce patient treatment burden while maintaining therapeutic efficacy. |
|
|
|
|
|
| Enfortumab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma: Subgroup Analyses Results from EV-302, a Phase 3 Global Study |
| Michiel Simon van der Heijden, MD, PhD |
| Michiel van der Heijden presents subgroup analyses from the phase 3 EV-302 trial, evaluating enfortumab vedotin (EV) combined with pembrolizumab versus chemotherapy in untreated, locally advanced or metastatic urothelial carcinoma (UC). The combination significantly improved both progression-free survival (PFS) and overall survival (OS) compared to platinum-based chemotherapy, with median PFS rising from 6.3 to 12.5 months and OS from 16.1 to 31.5 months. |
|
|
|
|
|
|
|
|
|
|
|
